Estimating the prevalence of persistent symptoms after SARS-CoV-2 infection (post-COVID-19 syndrome): a regional cross-sectional study protocol.

Publication date: May 30, 2025

The COVID-19 pandemic, driven by the SARS-CoV-2 virus, has had a significant global impact, with over 775 million cases reported and more than 7 million deaths as of July 2024. In Chile, approximately 5. 4 million people have been infected, with a substantial proportion experiencing persistent symptoms known as post-COVID-19 syndrome. This study aims to estimate the prevalence of post-COVID-19 syndrome in Punta Arenas, Chile, and to explore the associated symptoms, mainly focusing on psychological, physical and molecular impacts on the affected population. This cross-sectional study will use stratified random sampling to select a representative sample of 282 adults from Punta Arenas. Participants eligible for the study are those who had tested positive for SARS-CoV-2 by reverse transcription-quantitative PCR between July 2022 and July 2023. Data collection will include comprehensive clinical assessments, psychological evaluations and laboratory analyses of inflammatory biomarkers. Standardised instruments will be used to ensure consistency and reliability in measuring persistent symptoms. Statistical analyses will include descriptive statistics, regression models and subgroup analyses to identify risk factors and the prevalence of post-COVID-19 syndrome. The Human Research Ethics Committee of the Clinical Hospital of the University of Chile approved the study protocol (Memorandum No 007/2023). We will present the results in peer-reviewed publications and national and international professional and academic meetings. NCT05855382.

Open Access PDF

Concepts Keywords
775million Adult
Chile Chile
July COVID-19
Laboratory COVID-19
Pandemic Cross-Sectional Studies
Cross-Sectional Studies
Female
Humans
Male
Post-Acute COVID-19 Syndrome
Post-Acute COVID-19 Syndrome
Prevalence
Prevalence
Research Design
SARS-CoV-2

Semantics

Type Source Name
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH syndrome
disease MESH infection
disease MESH asymptomatic infections
disease MESH complications
disease IDO history
drug DRUGBANK Indoleacetic acid
disease MESH cognitive impairments
disease MESH diabetes mellitus
disease MESH obesity
disease MESH Epstein Barr virus infection
drug DRUGBANK Trestolone
disease IDO country
disease IDO blood
disease IDO cell
drug DRUGBANK Ilex paraguariensis leaf
disease MESH Gait
disease MESH posture
disease IDO process
disease MESH abnormalities
drug DRUGBANK Etoperidone
disease MESH symptom exacerbation
disease MESH Lifestyle
pathway REACTOME Immune System
disease MESH Post-Acute COVID-19 Syndrome

Original Article

(Visited 1 times, 1 visits today)